In Phase A, individuals will obtain distinctive doses and schedules of oral ABBV-744 tablet to recognize Safe and sound dosing regimen. Added contributors will likely be enrolled for the identified monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 are going to be offered as "insert-on" https://finnstuut.ssnblog.com/31212431/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results